Medicxi raises €500m for latest biotech fund Medicxi closes its fifth round, raising €500m for 'asset-centric' firms at all stages of development and taking the total raised in 10 years to €2bn+

Anglo-Swiss #lifesciences #investment company #Medicxi has raised €500 million (around $579 million) for its sixth fund, which will focus on supporting 'asset-centric' companies at all stages of #drugdevelopment.

pharmaphorum.com/news/medicxi...

Medicxi Celebrates Closure of €500 Million Fund V to Advance Biotechnology Ventures Medicxi has successfully closed its new €500 million Fund V, aimed at fostering innovative biotech companies that improve patient care and outcomes.

Medicxi Celebrates Closure of €500 Million Fund V to Advance Biotechnology Ventures #London #United_Kingdom #biotechnology #Fund_V #Medicxi

Servier bets $450m on Fragile X syndrome drug Servier has pushed its emerging neurology pipeline into the clinical trials stage by licensing a drug for Fragile X syndrome from the UK's Kaerus.

#biotech #Servier #FragileXsyndrome #FXS #rarediseases #KaerusBioscience #FRAXAResearchFoundation #FXStherapies #orphandrug #rarepaediatricdrugdesignation #FDA #neurodevelopmentaldisorder #raremovementdisorder #lifesciencesventurecapital #Medicxi #BKchannelmodulatorprogramme
zurl.co/EPSas